Related Experiment Videos
[Hyperhomocysteinemia as a risk factor for venous thrombosis]
H P Willems1, M den Heijer, H J Blom
1Ziekenhuis Leyenburg, afd. Hematologie, Den Haag.
Insights
Elevated homocysteine levels are linked to thrombosis risk. Current research is investigating if lowering homocysteine with vitamins like folic acid reduces vascular events, with trials ongoing.
Area of Science:
- Cardiovascular Science
- Thrombosis Research
- Nutritional Biochemistry
Context:
- Growing evidence links elevated homocysteine concentrations to arterial and venous thrombosis.
- Case-control studies identify high homocysteine as an independent risk factor for venous thromboembolism.
- The clinical significance of hyperhomocysteinemia in vascular disease is under active investigation.
Purpose:
- To review the association between homocysteine levels and thrombosis.
- To evaluate the potential of homocysteine-lowering therapies in preventing vascular events.
- To inform clinical practice regarding screening and treatment for hyperhomocysteinemia.
Summary:
- Increased homocysteine concentration is an independent risk factor for venous thromboembolism.
- The efficacy of folic acid, vitamin B12, and vitamin B6 in reducing vascular events requires further investigation.
- Randomized secondary prevention trials are underway to clarify the benefits of homocysteine reduction.
Impact:
- Highlights the need for evidence-based guidelines for managing hyperhomocysteinemia.
- Emphasizes the importance of awaiting results from ongoing clinical trials before widespread screening and treatment.
- Contributes to understanding the role of homocysteine in vascular disease pathogenesis and prevention.
Abstract:
In recent years research was done to elucidate the relation between an increased homocysteine concentration and arterial as well as venous thrombosis. Several case control studies showed that an elevated homocysteine concentration is an independent risk factor for primary and secondary venous thromboembolism. It is not clear whether lowering homocysteine levels by administration of folic acid, whether or not in combination with vitamin B12 and vitamin B6, decreases the risk of vascular events. Randomized secondary prevention trials are being conducted at this moment. It is recommended to await the results of these trials before screening for and treating of individuals with hyperhomocysteinaemia.